Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
RCM.US
id: 1002

R1 RCM (RCM) Inflated Revenue and Departures of Key Officers Case

  • In October 2023 RCM’s (RCM) revenues were chronically inflated, and that the Company has recently seen the departures of the CEO, CFO, CCO and CSO.
  • On it, $RCM fell 8.3%, losing $456M+ of shareholder value.
  • Investors may have grounds to suspect that RCM was systematically engaged in inaccurate reporting, which led to their losses.
On October 16, 2023, Jehoshaphat Research published a report alleging that RCM’s revenues and profits are grossly overstated, which will eventually “collapse,” and that the Company’s revenue is “chronically inflated.” The report also points out that RCM has recently seen the departures of the CEO, CFO, CCO and CSO, which speak to the risks that have surfaced.

On this news, $RCM fell 8.3% and lost over $456 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that RCM failed to timely disclose its inaccurate reporting practices, which led to their losses.

The case is already under investigation by at least one of the reputable law firms.
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
16 October 2023
Collecting participants…

R1 RCM Inc

R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-en...

    Ticker
    RCM.US
    ISIN
    US7493971052
    CIK
    1472595
    Sector
    Healthcare
    Industry
    Health Information Services
    Country
    USA
    Address
    434 W. Ascension Way, Murray, UT, United States, 84123